BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds

BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds

• Aurase shows dual action on chronic wound debridement and healing
• SolasCure preparing fund raising for clinical phase 2b/3
• Sequential growth forecasted in the next quarters for BRAINBiocatalysts

ZWINGENBERG, Germany, February 25, 2026 – BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biosolutions for industry, has published its financial figures for the first three months of the fiscal year 2025/26.

BRAIN Biotech Group generated Q1 revenue of € 11.9 million compared to € 13.1 million in the same period of the previous year, a decrease of 9.0 %. The group strongly improved the adjusted EBITDA to € 0.3 million from € -0.7 million in the same period last year, reflecting the strong performance of the BRAINBioIncubator segment. The BRAINBioIncubator segment benefitted from a milestone income of € 1.0 million from the deucrictibant program. The core segment BRAINBiocatalysts had the expected slow start to the year but is forecasted to show sequential growth over the next quarters.

The company today announced very positive news on its BRAINBioIncubator participation SolasCure. SolasCure is an independent clinical development company in which BRAIN Biotech holds a 35 % stake and additional production rights to the active pharmaceutical ingredient (API) tarumase. SolasCure has now successfully completed an extension study of Phase 2a clinical development. The treatment of chronic wounds with Aurase^® Wound Gel which combines a hydrogel with the enzymatic active ingredient tarumase shows both a 22 times more effective wound debridement and a 7 times accelerated healing compared to the current standard of care in the control group. SolasCure sees a total addressable market for the advanced treatment of chronic wounds of around US$ 4.3 billion in the US alone.

With this positive clinical data, SolasCure is now seeking a larger financing round to secure funding for the next steps in clinical development. Adriaan Moelker, CEO BRAIN Biotech, comments: “I am really thrilled by the clinical data the SolasCure team has been able to demonstrate. There is a large global need for innovation in advanced wound care. Aurase Wound Gel has demonstrated to accelerate wound debridement and healing at the same time and has therefore the potential to become a best-in-class first line treatment for chronic wounds with a large addressable market. We at BRAIN Biotech are very proud to have invented this enzyme and to be an active partner in its commercialization.”

Development of the segments

Revenues in the core segment BRAINBiocatalysts (enzymes, microorganisms and ingredients) decreased by 16.3 % from € 11.9 million to € 10.0 million in the reporting period. This decrease is largely attributable to lower sales of baking enzymes and to the beverage industry. The company is currently commissioning a new state-of-the-art joint production site in the Netherlands. The move and combination of production sites to and within the Netherlands was one root cause of lower sales in the quarter next to lower general customer demand. BRAIN Biotech Group expects to finalize commissioning of the new plant during Q2 2025/26. Adjusted EBITDA in the BRAINBiocatalysts segment decreased from € 0.8 million to € 0.5 million, mainly due to lower revenues and negative product mix effects. The company is forecasting sequential revenue growth for the BRAINBiocatalysts segment over the next quarters after the soft start in Q1.

Revenues within the BRAINBioIncubator segment (research-intensive R&D projects with industrial partners and own projects) rose strongly by € 0.7 million to € 1.9 million from € 1.2 million in the previous year. The company has been able to harvest a major milestone payment of € 1.0 million from the deucrictibant project for the treatment of hereditary angioedema. Milestone income in combination with lower personnel costs significantly improved adjusted EBITDA to € 0.7 million (€ - 0.7 million last year).

The BRAIN Biotech Holding mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing costs, group financing and M&A activities. The adjusted EBITDA for the holding was slightly lower at € -0.9 million compared to the previous year and fully within the budget planning.

Outlook

For the financial year 2025/26, BRAIN Biotech AG maintains its outlook for the core segment BRAINBiocatalysts with expected sales around last year’s level and an associated adjusted EBITDA margin of around 10 %. The company upgrades its guidance for the segment BRAINBioIncubator to a positive adjusted EBITDA (previously around break-even). It maintains its view that revenues in this segment are expected to grow markedly, targeting around € 5 million in the financial year.

Key financial data for the first three months of the fiscal year 2025/26

1 Revenues + change in inventories + other income including R&D grants

2 The reconciliation from adjusted to unadjusted EBITDA can be found in the 3M report for the period ended December 31^st, 2025

Further information

BRAIN Biotech AG 3M Report 2025/26:
https://www.brain-biotech-group.com/en/investors/financial-publications-calendar/financial-reports/

Financial Calendar:

https://www.brain-biotech-group.com/en/investors/financial-publications-calendar/financial-calendar/

+++

Contact Media

Dr. Stephanie Konle, PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations

Martina Schuster, Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

BRAIN Biotech

The BRAIN Biotech Group is a leader in researching, developing, and producing specialty enzymes, focusing on the food and life sciences industries. In addition, the group develops microbial production strains and scalable bioprocesses for the economic production of specialty enzymes and other proteins. BRAIN Biotech also offers customized biological solutions to the industry for more sustainable products and efficient processes.

BRAIN Biotech AG is the parent company of the BRAIN Biotech Group. The company´s activities are divided into two business segments: BRAINBiocatalysts (development, production, and distribution of specialty enzymes, microorganisms, and ingredients) and BRAINBioIncubator (research-intensive development projects and pharmaceuticals).

BRAIN Biotech operates its own fermentation facilities in the UK and has additional production sites in continental Europe and the US. BRAIN Biotech AG has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker symbol: BNN; ISIN: DE0005203947 / WKN: 520394). In the 2024/25 fiscal year, the group generated revenue of € 49.6 million with around 280 employees. For more information, visit: www.brain-biotech-group.com.

The BRAIN Biotech Group on social media and on the internet:

BRAIN Biotech Gruppe

Web: www.brain-biotech-group.com

LinkedIn: https://www.linkedin.com/company/brainbiotech

Threads: https://www.threads.net/@brainbiotechag

Bluesky: https://bsky.app/profile/brain-biotech-group.com

X: https://x.com/BRAINbiotech

Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg

Biocatalysts Ltd (Production, Distribution)

Website: https://www.biocatalysts.com/

LinkedIn: Biocatalysts Ltd on LinkedIn / BRAIN-Biocatalysts Life Science Solutions on LinkedIn

BRAIN Biotech Zwingenberg (Technologies & R&D Services)

Website: www.brain-biotech.com

LinkedIn: BRAIN Biotech Technologies & Services

AnalyticonDiscovery (R&D)

Web: https://ac-discovery.com/

LinkedIn: https://www.linkedin.com/company/analyticon-discovery/

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.